Malignant teratoma

Summary

Malignant teratoma (MONDO:0003514) is a disease (an umbrella term covering 7 Mondo subtypes) and 1 clinical trial. Top therapeutic interventions include ifosfamide. A subtype of teratoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 7 Mondo subtypes
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	malignant teratoma
Mondo ID	MONDO:0003514
DOID	DOID:5563
NCIT	C4287
UMLS	C4722083
MedGen	1652407
GARD	0023541
Is cancer (heuristic)	no

Also known as: malignant extragonadal teratoma · teratoma, malignant

Disease family

This is a subtype of teratoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › germ cell tumor › nongerminomatous germ cell tumor › teratoma › malignant teratoma

Related subtypes (12): cystic teratoma, central nervous system teratoma, gastric teratoma, fallopian tube teratoma, adult teratoma, mature teratoma, mediastinum teratoma, gonadal teratoma, teratoma with malignant transformation, nasopharyngeal teratoma, immature teratoma, sacrococcygeal teratoma

Subtypes (7): pineal region immature teratoma, immature gastric teratoma, intermediate malignant teratoma, immature ovarian teratoma, malignant teratoma of testis, malignant teratoma of mediastinum, immature extragonadal teratoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04684368	PHASE2	RECRUITING	A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IFOSFAMIDE	4	1